Extension of the thrombolytic time window with minocycline in experimental stroke

Stroke. 2008 Dec;39(12):3372-7. doi: 10.1161/STROKEAHA.108.514026. Epub 2008 Oct 16.

Abstract

Background and purpose: Thrombolysis with tPA is the only FDA-approved therapy for acute ischemic stroke. But its widespread application remains limited by narrow treatment time windows and the related risks of cerebral hemorrhage. In this study, we ask whether minocycline can prevent tPA-associated cerebral hemorrhage and extend the reperfusion window in an experimental stroke model in rats.

Methods: Spontaneously hypertensive rats were subjected to embolic focal ischemia using homologous clots and treated with: saline at 1 hour; early tPA at 1 hour, delayed tPA at 6 hours; minocycline at 4 hours; combined minocycline at 4 hours plus tPA at 6 hours. Infarct volumes and hemorrhagic transformation were quantified at 24 hours. Gelatin zymography was used to measure blood levels of circulating matrix metalloproteinase-9 (MMP-9).

Results: Early 1-hour thrombolysis restored perfusion and reduced infarction. Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion. Combining minocycline with delayed 6-hour tPA decreased plasma MMP-9 levels, reduced infarction, and ameliorated brain hemorrhage. Blood levels of MMP-9 were also significantly correlated with volumes of infarction and hemorrhage.

Conclusions: Combination therapy with minocycline may extend tPA treatment time windows in ischemic stroke.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers
  • Blood-Brain Barrier / drug effects
  • Brain Ischemia / blood
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / enzymology
  • Brain Ischemia / etiology
  • Cerebral Hemorrhage / blood
  • Cerebral Hemorrhage / chemically induced
  • Cerebral Hemorrhage / enzymology
  • Cerebral Hemorrhage / prevention & control
  • Cerebral Infarction / blood
  • Cerebral Infarction / enzymology
  • Cerebral Infarction / etiology
  • Cerebral Infarction / prevention & control
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Intracranial Embolism / blood
  • Intracranial Embolism / complications
  • Intracranial Embolism / drug therapy*
  • Intracranial Embolism / enzymology
  • Male
  • Matrix Metalloproteinase 9 / blood
  • Matrix Metalloproteinase Inhibitors*
  • Minocycline / administration & dosage
  • Minocycline / therapeutic use*
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Inbred SHR
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Reperfusion
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Biomarkers
  • Fibrinolytic Agents
  • Matrix Metalloproteinase Inhibitors
  • Neuroprotective Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator
  • Matrix Metalloproteinase 9
  • Minocycline